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Summary
Objective: Abnormal thyroid function in pregnant women is a matter of concern. Knowledge on the 
occurrence of known and unidentified thyroid function abnormalities in a large unselected cohort of 
pregnant women is warranted as part of the debate on benefits and risks of routine testing.  
Design: Cohort study
Participants: 14,323 pregnant women in the North Denmark Region, who had a blood sample drawn as 
part of the prenatal screening program in early pregnancy (2011-2015).
Measurements: TSH, free thyroxine, thyroid peroxidase and thyroglobulin antibodies were measured in 
the stored blood samples using an automatic immunoassay (ADVIA Centaur XPT, Siemens Healthineers).  
Cohort-, method-, and week-specific reference ranges were used for classification of maternal thyroid 
function and a cut-off of 60 U/ml was used for thyroid autoantibodies. Information in Danish nationwide 
registers was used to identify diagnosed and treated maternal thyroid disease. 
Results: Overall, 15.2% had thyroid function abnormalities in the early pregnancy and 14.9% were thyroid 
peroxidase and/or thyroglobulin antibody positive. Among women with known thyroid disease (n=365), the 
frequency of abnormal thyroid function was 45.7%, and 62.8% in women (n=172) who received current 
treatment in the pregnancy. When maternal thyroid disease was diagnosed in the years following pregnancy 
(n=313), 46.7% had abnormal thyroid function and 54.3% were thyroid peroxidase and/or thyroglobulin 
antibody positive in the early pregnancy.
Conclusion: Thyroid function abnormalities and thyroid autoantibodies were common in Danish pregnant 
women, particularly in women with known or later diagnosed thyroid disease, which raises concern about 
inadequately treated and unidentified abnormal thyroid function. 
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Introduction
Thyroid diseases are common endocrine disorders and contribute to the chronic disease burden in pregnant 
women.1 In early pregnancy, thyroid hormones are of maternal origin,2 and an adequate supply of maternal 
thyroid hormones are essential for the pregnancy as well as the developing fetus.3 Thyroid diseases in 
women who are or may become pregnant are mainly of autoimmune origin,4,5 and the presence of maternal 
thyroid autoantibodies is considered as a risk factor for pregnancy complications.6,7 
Overt thyroid disease in pregnant women should be treated to prevent maternal and foetal 
complications.6,7 However, studies from a number of countries have shown that women with known thyroid 
disease may not be adequately treated by the time they become pregnant.8–12 On the other hand, the 
management of pregnant women with subclinical thyroid disease or isolated changes in free thyroxine (fT4) 
as well as women who are positive for thyroid peroxidase antibodies (TPO-Ab) and/or thyroglobulin 
antibodies (Tg-Ab) is not clear,7 and evidence to recommend for or against routine testing of thyroid 
function in asymptomatic pregnant women remains insufficient.6,7 As part of this debate, it is important to 
provide data on the occurrence of undetected and untreated thyroid function abnormalities in pregnant 
women. 
Nationwide health registers in Denmark and other Nordic countries provide unique opportunities to 
identify pregnant women with unidentified thyroid function abnormalities, because information on known 
and later diagnosed thyroid disease can be obtained via linkage to hospital diagnoses and prescriptions of 
drugs. Among Danish women who were pregnant in the years 1997-2003,8 a high frequency of thyroid 
function abnormalities in early pregnancy was observed. This accounted for both women with known 
thyroid disease and women diagnosed in the years following pregnancy. These findings raised concern 
about the management of thyroid disease in pregnant women, but more recent data were warranted.8 
Mandatory iodine fortification of salt was implemented in Denmark in the year 2000, which has raised the 
iodine intake.13,14 This has changed the pattern of thyroid diseases in the population in general, especially in 
young individuals.15–17 Furthermore, clinical routine may have changed during the last decade18 and a re-
evaluation was warranted. 
This led us to retrospectively evaluate the frequency of thyroid function abnormalities in a recently 
established large cohort of pregnant women in the North Denmark Region, and to evaluate the frequency of 
thyroid autoantibodies (TPO-Ab and Tg-Ab). 
Materials and methods
Study population
The study is a retrospective, descriptive cohort study, and the study population is part of the North 
Denmark Region Pregnancy Cohort located in West Denmark.19 Denmark was previously iodine deficient 
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mandatory iodine fortification of salt was introduced in the year 2000 as has increased the iodine intake in 
the Danish population.13,14 However, iodine intake in Danish pregnant women living in West Denmark was 
below the recommended when evaluated in 2012 (median urinary iodine concentration in iodine 
supplement users: 109 g/l; non-users: 68 g/l) and 84.1% of the women were iodine supplement users.20 
In Denmark, all pregnant women are offered an early pregnancy prenatal screening for foetal 
chromosomal anomalies, which includes a blood sample drawn from the pregnant women at the first 
pregnancy visit in general practice. As previously described,19 serum residues from all samples drawn as 
part of the prenatal screening program in the North Denmark Region were consecutively collected in the 
period from June 2011 to January 2015, and the woman’s first blood sample in the first pregnancy in the 
study period was selected for the present study (n=14,323). All data were linked in Statistics Denmark and 
available in encrypted form so that no individuals could be identified by the researcher. The study was 
approved by the North Denmark Region Committee on Health Research Ethics (N-20150015) and the 
Danish Data Protection Agency (J.nr. 2008-58-0028).     
Biochemical measurements
The blood samples collected in early pregnancy were stored at minus 80 degrees Celsius until the 
biochemical analyses of maternal thyroid function and thyroid autoantibodies. TSH, fT4, TPO-Ab and Tg-
Ab were measured by an ADVIA Centaur XPT automatic immunoassay (Siemens Healthineers, Germany) 
from September 2015 to May 2016 at Department of Clinical Biochemistry, North Denmark Regional 
Hospital, Hjørring, Denmark, as described in detail previously.19 
In the present study, maternal thyroid function was classified from the method- and pregnancy week-
specific reference ranges previously established within the specific cohort using the biochemical 
measurements performed in 2015-2016 from a selected reference cohort, as previously described in detail.19 
Overt hyperthyroidism was defined by TSH <2.5th percentile and fT4 >97.5th percentile, and subclinical 
hyperthyroidism by TSH <2.5th percentile and fT4 within the reference ranges (5 women had suppressed 
TSH and fT4 slightly below the lower reference ranges and were classified with subclinical 
hyperthyroidism). Overt hypothyroidism was defined by TSH >97.5th percentile and fT4 <2.5th percentile, 
and subclinical hypothyroidism by TSH >97.5th percentile and fT4 within the reference ranges (6 women 
had elevated TSH and fT4 slightly above the upper reference ranges and were classified with subclinical 
hypothyroidism). Finally, isolated changes in maternal fT4 were defined by a fT4 concentration below the 
lower reference limit (hypothyroxinaemia) or above the upper reference limit (hyperthyroxinaemia) 
combined with a TSH within the reference range. For classification of maternal thyroid autoimmunity, cut-
off values of 60 U/ml given by the manufacturer for both TPO-Ab and Tg-Ab were applied. Furthermore, a 
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subtle changes in maternal thyroid autoimmunity in line with previous Danish investigations of non-
pregnant and pregnant women.17,21 
Diagnosis and treatment
The study relied on a single blood sample from each pregnant woman drawn in the early pregnancy. 
However, information on hospital diagnoses and redeemed prescription of drugs in Danish nationwide 
registers from 1994 to 2017 was used to evaluate if the women had diagnosed and treated thyroid disease 
before, during or after the pregnancy with follow-up until December 31, 2017. Treatment of thyroid disease 
was identified via registrations of redeemed prescriptions of drugs used for the treatment of thyroid disease 
and coded according to the Anatomic Therapeutic Chemical (ATC) Classification System in the Danish 
National Prescription Register.22 Diagnosis of thyroid disease (in- and outpatient visits) and thyroid surgery 
were identified via registrations in the Danish National Hospital Register23 and coded according to the 10th 
International Classification of Disease (ICD-10). 
The subtype of maternal thyroid disease was determined in a stepwise procedure. First, maternal thyroid 
disease was classified as thyroid cancer (n=18) if the woman had a diagnosis of thyroid cancer (ICD-10: 
DC739) at or after the date of thyroid surgery (ICD-10: KBAA20-KBAA60). Among the remaining 
women, maternal hyperthyroidism (n=301) was defined as any redeemed prescription of antithyroid drug 
(ATD) (ATC: H03B) and/or a hospital diagnosis of hyperthyroidism (ICD-10: DE05). Subsequently, 
maternal non-surgical hypothyroidism (n=273) was defined as any redeemed prescription of thyroid 
hormone (Levothyroxine (L-T4)) (ATC: H03A) and/or a hospital diagnosis of hypothyroidism (ICD-10: 
DE00, DE02, DE03, DE890) and no registration of thyroid surgery. The remaining women with surgical 
hypothyroidism and women with a hospital diagnosis of benign goiter (ICD-10: DE01 and DE04) were 
classified as benign goiter (n=77). Finally, few women (n=9) had only a hospital diagnosis of thyroiditis 
(ICD-10: DE06) or post-partum thyroiditis (ICD-10: DO905) and were classified with other maternal 
thyroid disease. 
The onset of maternal thyroid disease was defined by the date of first redeemed thyroid drug 
prescription or by the date of first hospital diagnosis of thyroid disease, whichever came first. However, if 
the subtype of thyroid disease was cancer, the onset was defined as the first date of a thyroid cancer 
diagnosis. For women with onset of thyroid disease before the blood sampling in early pregnancy, current 
treatment was defined by redeemed prescriptions of drugs in the period from 3 months prior to pregnancy 
start until the date of blood sampling. A subgroup of women (n=30) were classified with previous 
hyperthyroidism but received LT-4 in the pregnancy. In this group, six women had a registration of 










This article is protected by copyright. All rights reserved
Results were reported as the number of women and the frequency of biochemical thyroid function 
abnormalities and thyroid autoantibody positive among all women, as well as in women with known or 
later diagnosed thyroid disease according to treatment and type of diagnosed thyroid disease. Furthermore, 
results were evaluated according to information on maternal characteristics, which was available from the 
Danish Medical Birth Register24 (age, parity, pre-pregnancy body mass index (BMI), and smoking) and 
from Statistics Denmark (country of birth).  Predictors of abnormal maternal thyroid function and thyroid 
autoimmunity were evaluated in univariate stratified analyses and in multivariate logistic regression models 
with dichotomous variables (odds ratio (OR) with 95% confidence interval (CI)). Statistical analyses were 
preformed using STATA version 15 (StataCorp, College Station, TX). 
Results
Altogether 14,323 pregnant women in the North Denmark Region were included in the study. The women 
had a median age of 30 years (ranging from 16 to 51 years) and 88.3% were born in Denmark. Blood 
samples were drawn in median pregnancy week 10 (range: 4 to 20). A total of 678 (4.7%) women had 
registrations of thyroid disease in nationwide registers and were diagnosed before (n=365) or after (n=313) 
the blood sampling. 
Overall findings
Overall, 15% of the women had TSH and/or fT4 outside the pregnancy week specific reference ranges and 
were classified with thyroid dysfunction (Table 1). All subtypes of thyroid dysfunction were observed, and 
hypothyroidism was the most frequent thyroid function abnormality (Table 1). Altogether, 47 women 
(0.3%) had TSH above 10 mIU/l. As expected, subclinical thyroid function abnormalities were more 
frequent than overt abnormalities, and 5% of the women had isolated changes in fT4. Considering thyroid 
autoimmunity, 15% of the women were positive for TPO-Ab and/or Tg-antibodies (Table 1) with 10% 
being TPO-Ab positive (irrespective of Tg-Ab status) and 10% being Tg-Ab positive (irrespective of TPO-
Ab status). 
When analyses were restricted to women who gave birth to a singleton live-born child (89.9%), the 
frequencies of biochemical thyroid function abnormality and thyroid autoimmunity in early pregnancy were 
comparable to the overall figures (thyroid dysfunction: 14.9%; TPO-Ab and/or Tg-Ab: 14.8%). 
Furthermore, the exclusion of women diagnosed with thyroid cancer (n=18) did not change results. Finally, 
when the cut-offs for thyroid autoantibodies were reduced to 30 U/ml for TPO-Ab and 20 U/ml for Tg-Ab 
the number of thyroid autoantibody positive women increased (TPO-Ab and/or Tg-Ab: 53.2%; Total TPO-
Ab positive 45.7%; Total Tg-Ab positive 22.4%). 
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The frequencies of thyroid function abnormalities and thyroid autoimmunity in early pregnancy were 
considerably higher among women with known or later diagnosed thyroid disease (Table 2 and 3) as 
compared with the overall findings. Thus, 167 of the 365 women with known thyroid disease had abnormal 
thyroid function in the early pregnancy and the frequency of thyroid autoimmunity was similarly high 
(Table 2). The highest frequency of thyroid function abnormalities was observed among women who 
received current treatment (Table 2). When stratified by subtype of disease and treatment in early 
pregnancy (Figure 1), the frequency of thyroid function abnormalities was high in women who received 
ATD (Figure 1A) and in women treated with L-T4 (Figure 1B). Notably, thyroid function abnormalities 
were also observed in women who were previously diagnosed with thyroid disease but received no current 
treatment in the pregnancy (Figure 1). A small subgroup of the women (n=15) were newly diagnosed with 
thyroid disease in the early pregnancy. The frequency of thyroid function abnormalities was high in this 
group (80%) and included both hyperthyroidism and hypothyroidism. However, the frequencies of thyroid 
function abnormalities among women with known disease were similar after the exclusion of this group 
(thyroid dysfunction: 44.3%; TPO-Ab and/or Tg-Ab: 58.0%). 
Among women diagnosed with thyroid disease after the blood sampling, the frequency of thyroid 
function abnormalities in early pregnancy was similarly high and dominated by both overt and subclinical 
findings (Table 3). When stratified by subtype of disease (Figure 1), 36 (27.7%) of the 130 women with 
later diagnosis of hyperthyroidism had overt or subclinical hyperthyroidism as evaluated from the early 
pregnancy blood sample (Figure 1A). On the other hand, 74 (52.8%) of the 140 women with later diagnosis 
of hypothyroidism had hypothyroidism in early pregnancy (Figure 1B). Notably, 170 of the 313 women 
with later diagnosis of thyroid disease were positive for TPO-Ab and/or Tg-Ab in early pregnancy. The 
women were followed for a median of 4.2 years after the pregnancy for diagnosis of thyroid disease (range 
2.3-6.5 years). When the follow-up period was restricted to 2 years, the number of women with onset of 
thyroid disease was lower (n=196), but the frequencies of biochemical thyroid dysfunction and thyroid 
autoimmunity were at a similar level (thyroid dysfunction 49.5%; TPO-Ab and/or Tg-Ab: 55.1%).
Maternal characteristics 
The frequency of thyroid function abnormalities and thyroid autoimmunity differed according to maternal 
characteristics, and statistical significant predictors were observed in multivariate analyses (Table 4). 
Higher maternal age was a risk factor for biochemical hypothyroidism as well as thyroid autoimmunity. On 
the other hand, higher parity and non-Danish origin were risk factors for hyperthyroidism. Maternal 
smoking was 
associated with a reduced risk of hypothyroidism and thyroid autoimmunity, whereas maternal BMI ≥ 30 
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BMI reduced the risk of hyperthyroidism, and this was most pronounced for BMI ≥ 30 kg/m2, whereas the 
OR for BMI 25-30 kg/m2 was 0.81 (0.65-1.01).  
Discussion
Principal findings
In a large cohort of 14,323 pregnant women in the North Denmark Region, the frequency of thyroid 
function abnormalities and thyroid autoimmunity was high. The linkage between thyroid function 
measurements in blood samples from pregnant women and information in nationwide registers provided the 
unique opportunity to address thyroid function in women with known thyroid disease and in women first 
time diagnosed with thyroid disease in the years following the pregnancy. The frequency of thyroid 
function abnormalities in early pregnancy was even higher in these groups, which raise concern about 
inadequately treated as well as undetected and untreated thyroid disease in Danish pregnant women.
Previous investigations
Previous investigations on the frequency of thyroid function abnormalities in Danish pregnant women 
included women who were pregnant in the years 1997-2003 (nationwide study)8 and in 2008 (East 
Denmark).25 Studies of the general Danish population have shown, that the mandatory iodine fortification 
has been followed by an increase in the incidence of hyper- and hypothyroidism, particularly in young 
individuals, and it is debated whether this increase is explained by an increase in the occurrence of 
autoimmune thyroid disease.15,16 Furthermore, the number of individuals with TPO-Ab and/or Tg-Ab has 
increased, most pronounced in young women and at low antibody levels.17 With these changes in iodine 
intake during the last 20 years and a possible change in clinical routine for treating thyroid disease,18 
follow-up on the occurrence of thyroid disease in pregnant women and specification of subtypes of disease 
was warranted.
The present study was conducted in West Denmark more than 10-years after the implementation of 
iodine fortification of salt, and the frequency of thyroid function abnormalities in pregnant women was 
15% and parallel to previous Danish investigations.8,25 However, methodological differences make it 
difficult to compare results of the different studies, and the cross-sectional design from a single 
measurement of thyroid function in early pregnancy should be acknowledged.
The presence of thyroid autoantibodies are related to a process of autoimmune destruction of thyroid 
tissue.26 Still, thyroid disease may not be present.27 Considering the occurrence of thyroid autoimmunity, a 
recent study from East Denmark showed a marked increase in the presence of both TPO-Ab and Tg-Ab in 
Danish pregnant women after the iodine fortification of salt, and it was dominated by an increase in low 
autoantibody titers.21 These findings were comparable to the figures on thyroid autoimmunity that we now 
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general, the frequency of thyroid autoantibodies in pregnant women varies worldwide and across 
populations with different iodine intake. Thus, the prevalence of TPO-Ab positive women was recently 
reported to range from 4.7 to 15.2% and Tg-Ab positive women from 4.2 to 12.7%.28 
Women with known thyroid disease
Overt thyroid disease in pregnant women should be adequately treated to prevent maternal and foetal 
complications.7 Preconception counselling and early detection of a pregnancy is recommended when the 
mother suffers from both hyper- and hypothyroidism.7 Optimally a pregnancy should be planned and the 
women should be informed to contact the responsible physician as soon as a pregnancy is detected.7 For 
women treated with ATD, the choice of drug is of importance considering the risk of birth defects.29  In 
women treated with L-T4, the focus is on the need to increase the dose from the early pregnancy.7 
We observed a very high frequency of early pregnancy thyroid function abnormalities in women with 
known thyroid disease, which was dominated by a high frequency of both overt and subclinical 
abnormalities. Similar figures have been observed in different countries9–12 and are also in line with the 
findings in the nationwide study of pregnant women in Denmark with data collected nearly 20 years ago.8 
These findings raise important concerns about the management of thyroid disease in pregnant women. 
However, some clinical aspects should be considered in the interpretation of the results. According to 
clinical guidance overtreatment with ATD should be avoided to prevent foetal hypothyroidism, and it is 
recommended to keep maternal thyroxine in the upper part of the reference range or slightly above the 
upper level during treatment.7 This may to some extent explain our findings of biochemical subclinical 
hyperthyroidism among nearly 30% of women with known hyperthyroidism treated with ATD. On the 
other hand, the target for TSH in pregnancy among women treated for hypothyroidism with L-T4 is in the 
lower half of the reference range.7 Thus, our finding of biochemical hypothyroidism in 50% of Danish 
pregnant women in current treatment with L-T4 is a serious concern and stresses a need to improve the 
management of women with known hypothyroidism. Such improvements should include awareness among 
general practitioners, endocrinologists, and the patients. In Denmark, hypothyroidism in pregnant women is 
managed by endocrinologists, and timely referral from general practice, preconception counselling as well 
as early pregnancy detection are important aspects.  
Women with later diagnosis of thyroid disease
A unique methodology in the present study was the possibility to identify women who had no known 
thyroid disease at the time of pregnancy, but were diagnosed in the years following the pregnancy. This 
was possible via linkage to information in Danish nationwide registers. We observed a high frequency of 
thyroid function abnormalities in the early pregnancy in this group of women. This was in line with the 
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another thyroid function assay and blood samples that had been drawn in years around the implementation 
of iodine fortification and stored for a longer period prior to analys.8 The findings, in two independent 
Danish cohorts, raise concern about the presence of undetected and untreated thyroid function 
abnormalities in pregnant women. The evaluation was based on a single measurement of thyroid function 
in both cohorts and repeated sampling would have been warranted. However, the specific high frequency of 
thyroid function abnormalities as well as thyroid autoimmunity among women who were diagnosed with 
thyroid disease in the years following the pregnancy suggest that the abnormalities were likely to persist. 
The findings are important contributions to the ongoing debate on benefits and risk of routine testing of 
thyroid function in pregnant women.30 Notably, the frequency of maternal overt hypothyroidism observed 
in the present and other studies was considerably higher than congenital hypothyroidism which might 
favour routine testing.30 Other aspects of this debate include the optimal timing of maternal thyroid function 
testing in pregnancy, and our results do not add to the discussion on the potential benefits of preconception 
testing. Finally, the subsequent consideration is whether the abnormalities affect the outcome of a 
pregnancy. The adverse outcomes of untreated maternal overt thyroid function abnormalities are evident.7 
On the other hand, results of previous investigations are not consistent regarding the role of smaller 
deviations in maternal thyroid function.28,31,32 Thus, additional studies on the outcomes of different types 
and severity of maternal thyroid function abnormalities are warranted.
Methodological comments
A strength of the present study was the large and unselected study population of pregnant women and the 
possibility to measure thyroid function as well as thyroid autoantibodies. The blood samples were collected 
as part of the prenatal screening program for chromosomal anomalies and the participation rate in this 
program is high (>90%),33 which reduces the risk of selection bias.
The validity of the Danish nationwide registers is considered high.22,23 The diagnosis of thyroid disease 
in the DNHR revealed misclassification in less than 2% of 900 cases.34 However, the DNHR do not reflect 
completeness regarding diseases treated solely in general practice, but the combined use of hospital 
diagnoses and redeemed prescriptions of drugs further improves the completeness regarding classification 
of disease in the general Danish population.23
The blood samples were stored at minus 80 degrees Celsius until the measurement of maternal thyroid 
function parameters and thyroid autoantibodies. Previous studies have shown that thyroid function 
parameters as well as thyroid autoantibodies are stable for more than 20 years when stored at minus 25 
degrees Celcius.35  We measured TSH and fT4 using an automated immunoassay. Measurement of free 
thyroid hormones using an indirect method is prone to alternations in binding proteins, which may be 
method dependent and may challenge the comparison between results of different assays.36,37 However, we 
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maternal thyroid function. We measured TPO-Ab and Tg-Ab, but not TSH-receptor antibodies, which 
limited the possibility to distinguish between hyperthyroidism of Graves’ disease and gestational 
hyperthyroidism.  
The study was based on routinely collected blood samples that were stored in a biobank. The linkage to 
Danish nationwide registers provided information on maternal thyroid disease and other covariates, 
however, no information was available on maternal use of iodine supplementation in pregnancy and urine 
samples were not collected for measurement of urinary iodine concentration. Such data would be warranted 
to evaluate results in relation to population iodine status and iodine fortification.  
In line with other reports38 we observed that maternal characteristics predicted the presence of different 
thyroid function abnormalities. Such characteristics are important to consider in outcome studies, since they 
may also associate with the outcomes of pregnancy or child development as well as introduce confounding. 
Perspectives
The present study demonstrates a high frequency of thyroid function abnormalities in a large cohort of 
Danish pregnant women. The findings raise concern about inadequately treated and even untreated 
maternal thyroid disease in early pregnancy and call for a focus on optimal management and control of 
thyroid disease in women with known thyroid disease. Finally, results add data to the debate on routine 
testing of thyroid disease in pregnant women to identify undiagnosed disease, and call for studies 
evaluating the outcome of undetected and untreated thyroid function abnormalities in pregnant women.
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Table 1 Frequency of biochemical thyroid function abnormalities 
and thyroid autoimmunity in the total cohort (n=14,323)
a
 
Abnormal TSH and/or fT4
b TPO-Ab >60 U/ml and/or Tg-Ab >60 U/ml
Abbreviations: fT4, free thyroxine; Tg-Ab, thyroglobulin antibodies; TPO-Ab, 
thyroid peroxidase antibodies
n %







Abnormal fT4 716 5.0
Hyperthyroxinemia 258 1.8
Hypothyroxinemia 458 3.2
Thyroid autoimmunityb 2129 14.9
Total TPO-Ab positive 1558 10.9
Only TPO-Ab positive 634 4.4
Total Tg-Ab positive 1495 10.4
Only Tg-Ab positive 571 4.0
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Table 2 Frequency of biochemical thyroid function abnormalities and thyroid autoimmunity in women 
with diagnosis of thyroid disease prior to blood sampling in early pregnancy  
a Abnormal TSH and/or fT4
b TPO-Ab >60 U/ml and/or Tg-Ab >60 U/ml
Abbreviations: fT4, free thyroxine; Tg-Ab, thyroglobulin antibodies; TPO-Ab, thyroid peroxidase antibodies 
All  women with 
known disease 
(n=365)
No medical treatment 
in early pregnancy 
(n=193)
Medical treatment 
in early pregnancy 
(n=172)
n % n % n %
Thyroid dysfunctiona 167 45.7 59 30.6 108 62.8
Hyperthyroidism 41 11.2 16 8.2 25 14.5
Overt 14 3.8 3 1.6 11 6.4
Subclinical 27 7.4 13 6.6 14 8.1
Hypothyroidism 107 29.3 37 19.2 70 40.7
Overt 22 6.0 10 5.2 12 7.0
Subclinical 85 23.3 27 14.0 58 33.7
Abnormal fT4 19 5.2 6 3.2 13 7.6
Hyperthyroxinemia 13 3.6 3 1.6 10 5.8
Hypothyroxinemia 6 1.6 3 1.6 3 1.8
Thyroid autoimmunityb 213 58.3 87 45.0 126 73.3
Total TPO-Ab positive 189 51.8 74 38.3 115 66.9
Only TPO-Ab positive 61 16.7 22 11.4 39 22.7
Total Tg-Ab positive 152 41.6 65 33.6 87 50.6
Only Tg-Ab positive 24 6.5 13 6.7 11 6.4
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Table 3 Frequency of biochemical thyroid function abnormalities and thyroid autoimmunity in women 
diagnosed with thyroid disease after the blood sampling in early pregnancy (n=313) 
a Abnormal TSH and/or fT4
b TPO-Ab >60 U/ml and/or Tg-Ab >60 U/ml
Abbreviations: fT4, free thyroxine; Tg-Ab, thyroglobulin antibodies; TPO-Ab, 
thyroid peroxidase antibodies
n %







Abnormal fT4 23 7.4
Hyperthyroxinemia 14 4.5
Hypothyroxinemia 9 2.9
Thyroid autoimmunityb 170 54.3
Total TPO-Ab positive 145 46.3
Only TPO-Ab positive 39 12.5
Total Tg-Ab positive 131 41.8
Only Tg-Ab positive 25 8.0
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Table 4 Predictors of biochemical thyroid function and thyroid autoimmunity
Abbreviations: BMI, body mass index; CI, confidence interval; fT4, free thyroxine; OR, odds ratio; ref., reference group 
a The reference group for the dependent variables hyperthyroidism, hypothyroidism, isolated abnormal and fT4 was all women with 
TSH and fT4 within the pregnancy week specific reference ranges, and for thyroid autoimmunity it was thyroid autoantibody 
negative women. 
b Adjusted model included all predictors mentioned in the table. 







Maternal age (ref.: < 35 years)
Hyperthyroidism 1.35 1.09-1.68 1.18 0.94-1.48
Hypothyroidism 1.24 1.03-1.48 1.28 1.06-1.54
Isolated abnormal fT4 1.00 0.81-1.24 0.97 0.78-1.22
Thyroid autoimmunityc 1.41 1.25-1.59 1.37 1.21-1.56
Maternal parity (ref.: nulliparous)
Hyperthyroidism 1.65 1.37-1.97 1.58 1.31-1.91
Hypothyroidism 0.87 0.76-1.01 0.82 0.71-0.96
Isolated abnormal fT4 1.01 0.86-1.18 1.01 0.85-1.18
Thyroid autoimmunityc 1.14 1.04-1.26 1.07 0.97-1.18
Maternal origin (ref.: born in Denmark) 
Hyperthyroidism 1.62 1.28-2.05 1.50 1.18-1.90
Hypothyroidism 1.06 0.85-1.32 1.07 0.85-1.33
Isolated abnormal fT4 0.95 0.74-1.22 0.99 0.77-1.27
Thyroid autoimmunityc 1.13 0.98-1.31 1.10 0.95-1.27
Maternal smoking (ref.: non-smoking)
Hyperthyroidism 0.90 0.67-1.20 0.97 0.73-1.30
Hypothyroidism 0.65 0.50-0.84 0.64 0.49-0.83
Isolated abnormal fT4 1.08 0.85-1.37 1.05 0.83-1.34
Thyroid autoimmunityc 0.70 0.59-0.82 0.71 0.60-0.84
Maternal pre-pregnancy BMI (ref.: < 30 kg/m2)
Hyperthyroidism 0.48 0.35-0.66 0.49 0.35-0.67
Hypothyroidism 1.41 1.18-1.68 1.44 1.21-1.73
Isolated abnormal fT4 1.42 1.17-1.72 1.39 1.14-1.70
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Legends to figures
Figure 1 
Frequencies of biochemical hyperthyroidism (A) and hypothyroidism (B) among women with diagnosed 
hyperthyroidism (A) and hypothyroidism (B), and stratified by current treatment (antithyroid drug (ATD) 
and Levothyroxine (L-T4)) in early pregnancy as well as onset of disease. Women with known 
hyperthyroidism who received current treatment with L-T4 (n=30) as well as women who received current 
L-T4 after previous thyroid surgery of benign goiter or cancer (n=14) were not shown.    
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